About IRADIMED CORP
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories.
It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
IRMD operates in the Manufacturing | Medical Equipment | headquartered in Winter Park, Florida | approximately 110 employees | led by CEO Roger Susi.
The $904.8M question: What happens when a company this good becomes this expensive?
In the alphabet soup of healthcare investing, few stories capture the tension between innovation and regulation quite like IRADIMED CORP. The company stands at the intersection of scientific possibility and market reality.
At $904.8M in market capitalization, IRADIMED CORP (IRMD) currently ranks #128 in our quantitative model, with a composite score of 77.8/100. That places it firmly in "Strong Buy" territory — our highest conviction rating.
But here's the thing about stocks priced for perfection: They leave no room for error.
The Numbers That Matter
Let's start with what's undeniably true. Our 6-factor model gives IRMD the following scores:
| Factor | Score | Weight | Assessment |
|---|---|---|---|
| Quality | 90/100 | 30% | Exceptional |
| Value | 77/100 | 15% | Fair |
| Momentum | 82/100 | 25% | Accelerating |
| Investment | 32/100 | 10% | Low |
| Stability | 57/100 | 10% | Volatile |
| Short Interest | 57/100 | 10% | Normal |
The quality score of 90/100 is the headline here. It reflects profitability metrics that would make most CFOs weep with envy:
- ROE: 22.2%
- Net Margin: 26.3%
- Gross Margin: 77.8%
These aren't just good numbers. They're the kind of numbers that make IRMD a "must-own" stock for institutional portfolios.
The Bull Case
"If you could design a business in a laboratory, it would look something like IRMD."
The bull case writes itself:
- Quality is persistent. Academic research shows high-quality stocks outperform by 4-6% annually over long periods. IRMD is quality defined.
- Momentum is real. With a momentum score of 82/100, the stock has been recognized by the market — and momentum tends to persist.
- The moat is deep. Companies with these margins don't lose them easily. The competitive position is entrenched.
The Bear Case
But here's what keeps value investors up at night:
- Valuation compression risk. At current levels, the stock is priced for continued perfection. Any stumble — a missed quarter, a competitive threat, a macro slowdown — could compress the multiple from 42.7x to the low 20s. That's a 20-30% decline without anything fundamentally "wrong."
- The crowded trade problem. When everyone owns a stock, who's left to buy? Momentum works until it doesn't.
- Mean reversion. Trees don't grow to the sky. At some point, growth decelerates.
The Valuation Framework
| Scenario | Assumption | Fair Value | Upside/Downside |
|---|---|---|---|
| Bear | Multiple compression to 20x | -20% | Downside |
| Base | Current trajectory continues | +10-15% | Modest upside |
| Bull | Momentum accelerates | +30-40% | Significant upside |
The risk-reward is ... fine. Not exceptional. Not terrible. Just fine.
The Bottom Line
IRADIMED CORP is exactly what it appears to be: a high-quality business with strong momentum trading at a premium price. Whether that's attractive depends entirely on what kind of investor you are.
For long-term, buy-and-hold investors, IRMD is a core holding. For value investors or short-term traders, look elsewhere.
The company is priced for perfection — and in markets, as in life, perfection is a fragile thing.
⭐⭐⭐⭐⭐ Rating: 5-Star Strong Buy
Score: 77.8/100 | Rank: #128 of 3,571 stocks
Sector: Healthcare
This analysis reflects the views of Blank Capital Research as of February 16, 2026. It is not investment advice. Past performance does not guarantee future results.